Baseline patient characteristics at 0 and 11 years after the COBRA trial
| Baseline | 11-Year follow-up | |||
|---|---|---|---|---|
| Characteristics* | COBRA (n=76) | SSZ (n=79) | COBRA (n=69) | SSZ (n=65) |
| Age, years† | 50 (12) | 49 (12) | 61 (12) | 60 (12) |
| No. of women† | 50 (66%) | 41 (52%) | 47 (68%) | 34 (52%) |
| Median (range) disease duration, months† | 4 (1–24) | 4 (1–23) | 142 (131–154) | 140 (131–155) |
| DAS28 score‡ | 5.9 (1.0) | 5.7 (1.0) | 3.0 (1.2) | 3.0 (1.4) |
| Doctor VAS‡,§ | 53 (24) | 51 (22) | 17 (17) | 16 (15) |
| HAQ score‡ | 1.5 (0.1) | 1.4 (0.1) | 1.0 (0.7) | 0.9 (0.7) |
| Pain VAS‡,§ | 55 (21) | 54 (22) | 28 (23) | 25 (23) |
| Fatigue VAS‡,§ | NA | NA | 31 (25) | 27 (28) |
| Erosions on hand or foot radiographs¶ | 55 (74%) | 59 (79%) | 52 (87%) | 42 (81%) |
| Positive IgM rheumatoid factor | 59 (78%) | 57 (72%) | NA | NA |
↵* Data are mean (SD) or count (%) unless noted otherwise.
↵† For 11 years of follow-up: all patients, except 18 dead, 3 missing.
‡ 62 COBRA patients, 52 SSZ patients.
↵§ 0 (no active disease/pain/fatigue) to 100 (the worst possible active disease/pain/fatigue).
↵¶ Patients with available baseline radiographs/11-year radiographs; combined treatment group (n=74/60), sulfasalazine group (n=75/52).
COBRA, ‘COmbinatie therapie Bij Rheumatoide Artritis’; DAS28, 28-joint Disease Activity Score; HAQ, Health Assessment Questionnaire; NA, Not available; SSZ, sulfasalazine; VAS, visual analogue scale.